RxDoctor Payments Data

Ivan Mikolaenko, MD

Neurology · Coral Springs, FLNPI 1023231883

Payments from drug & device makers

$22,558in general payments, 2019–2025

Across 813 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Otsuka America Pharmaceutical, Inc.$2K
  • SK Life Science, Inc.$1K
  • Axsome Therapeutics, Inc.$1K
  • UCB, Inc.$959
  • Pfizer$826
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$230%
  • Food & beverage$22,27299%
  • Education$2631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie175$5,132
Otsuka America Pharmaceutical, Inc.41$1,850
SK Life Science, Inc.51$1,495
Axsome Therapeutics, Inc.32$1,175
UCB, Inc.60$959
Pfizer39$826
Teva Pharmaceuticals USA, Inc.22$810
Neurelis, Inc.21$716
Lundbeck LLC29$677
Scilex Pharmaceuticals Inc.28$631
Biogen29$601
Amneal Pharmaceuticals LLC22$559
Amgen(2 entities)22$505
Kyowa Kirin, Inc.14$461
Takeda Pharmaceuticals U.S.A., Inc.19$444
Acadia Pharmaceuticals Inc9$401
Neurocrine Biosciences, Inc.6$380
Azurity Pharmaceuticals, Inc.22$357
Lilly USA, LLC11$318
MDD US Operations, LLC12$288
Argenx US, Inc.3$279
Eisai Inc.3$273
Kowa Pharmaceuticals America, Inc.26$252
Harmony Biosciences LLC14$250
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$235
Sunovion Pharmaceuticals Inc.7$226
Genentech USA, Inc.7$174
Acorda Therapeutics, Inc10$171
Boston Scientific2$158
ANI Pharmaceuticals, Inc.6$139
4web, Inc.1$135
Alkermes, Inc.1$126
Mallinckrodt Hospital Products Inc.1$125
Sanofi1$120
Merck6$118
Novartis5$115
AstraZeneca(2 entities)5$106
Merz Pharmaceuticals, LLC3$100
Vanda Pharmaceuticals Inc.5$81
Almatica Pharma LLC3$74
Abbott3$66
Medtronic1$60
Forte Bio-pharma LLC2$59
Supernus Pharmaceuticals, Inc.4$49
Arbor Pharmaceuticals, Inc.3$49
Sumitomo Pharma America, Inc.2$46
Bausch Health US, LLC2$45
Impel Pharmaceuticals Inc.2$38
Catalyst Pharmaceuticals, Inc.2$37
CSL Behring2$36
Impel Pharmaceuticals LLC2$30
Corium, LLC1$25
Altathera Pharmaceuticals LLC1$25
Avanir Pharmaceuticals, Inc.1$24
Bristol Myers Squibb1$24
Jazz Pharmaceuticals Inc.1$24
Idorsia Pharmaceuticals US Inc1$21
Nevro Corp.1$21
Xeris Pharmaceuticals, Inc.1$21
Inspire Medical Systems, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,558 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$707,151
Medicare patients
771
Services billed
14,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Potassium748$1,815,980
Nurtec OdtRimegepant Sulfate913$1,641,772
Diclofenac Sodium1,314$1,310,904
RexultiBrexpiprazole266$375,391
Dihydroergotamine Mesylate330$373,384
ZtlidoLidocaine923$319,445
UbrelvyUbrogepant168$243,840
Diclofenac Epolamine681$216,449
QuliptaAtogepant170$177,468
NamzaricMemantine Hcl/Donepezil Hcl241$148,207
Kesimpta PenOfatumumab11$111,742
NuplazidPimavanserin Tartrate16$108,984
HorizantGabapentin Enacarbil185$107,485
NourianzIstradefylline41$92,975
VraylarCariprazine Hcl57$78,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Lyrica, Eliquis, Zavzpret$826$1,696,126978 claims
AbbVieUbrelvy, Qulipta, Namzaric, Vraylar, Linzess$5,132$680,953688 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,850$375,391266 claims
Scilex Pharmaceuticals Inc.Ztlido$631$319,445923 claims
Acadia Pharmaceuticals IncNuplazid$401$108,98416 claims
Arbor Pharmaceuticals, Inc.Horizant$49$107,485185 claims
Kyowa Kirin, Inc.Nourianz$461$92,97541 claims
UCB, Inc.Briviact, Neupro$959$75,50473 claims
Amneal Pharmaceuticals LLCRytary$559$58,01578 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$444$41,19174 claims
MerckBelsomra$118$38,03189 claims
Neurelis, Inc.Valtoco$716$36,32217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Coral Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →